NuraLogix Announces Integration Availability of its Highly Anticipated
Anura™ Telehealth Platform
NuraLogix, a global pioneer in Affective Ai1, is pleased to announce the availability of its highly-anticipated Anura™ Telehealth
solution for integration into healthcare professionals’ telehealth offerings. Powered by our cloud based Affective Ai platform,
DeepAffex™, Anura™ Telehealth enables real-time assessment of vital signs during video consultation sessions.
NuraLogix Researchers Announce the Capability to Predict Risk for Fatty Liver Disease and Blood Biomarker Health Issues Using Any Video-Enabled Device
Researchers at NuraLogix, a global pioneer of contactless health monitoring through its patented Transdermal Optical Imaging (TOI™) technology, have announced they have developed AI models that can predict a person’s risk of having fatty liver disease (FLD) using facial blood flow patterns.
CES 2023: NuraLogix Unveils Anura™ Telehealth Allowing Continuous Health and Vital Sign Measurements To be Taken on Video Calls
NuraLogix, global pioneers of contactless health monitoring whose technology can take over 30 medical-grade health vitals using any video-enabled device, unveils Anura™ Telehealth, a platform that performs continuous health and vital sign measurements while on a video call.
NuraLogix Announces Holy
Grail of Blood Pressure
Researchers at NuraLogix, a global leader in Health Tech AI,
announced today that they have achieved the ‘Holy Grail’ of
contactless blood pressure (BP) measurement using the
company’s TOI™ based Anura™ app.
HLTH 2022: NuraLogix
researchers announce the
capability to assess Type 2
diabetes and blood biomarker
health issues using any video-
Researchers at NuraLogix, a global pioneer of contactless health monitoring through its patented Transdermal Optical Imaging (TOI™) technology, has announced that it is adding the ability to perform metabolic and blood biomarker health risk assessments for various chronic conditions to its Anura platform.